NEW YORK (360Dx) – With Roche's entry into the digital hematology space, the firm is looking to crack open a $2.8 billion market opportunity that doesn't even include point-of-care, or "specialty marker," hematology testing.
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.